ML133 HCl

CAS No. 1222781-70-5

ML133 HCl ( —— )

Catalog No. M17888 CAS No. 1222781-70-5

ML133 HCl is a selective potassium channel inhibitor for Kir2.1 with IC50 of 1.8 μM (pH 7.4) and 290 nM (pH 8.5), has no effect on Kir1.1 and weak activity for Kir4.1 and Kir7.1.

Purity : 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 39 Get Quote
10MG 55 Get Quote
25MG 97 Get Quote
50MG 156 Get Quote
100MG 259 Get Quote
200MG 336 Get Quote
500MG 566 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    ML133 HCl
  • Note
    Research use only, not for human use.
  • Brief Description
    ML133 HCl is a selective potassium channel inhibitor for Kir2.1 with IC50 of 1.8 μM (pH 7.4) and 290 nM (pH 8.5), has no effect on Kir1.1 and weak activity for Kir4.1 and Kir7.1.
  • Description
    ML133 HCl is a selective potassium channel inhibitor for Kir2.1 with IC50 of 1.8 μM (pH 7.4) and 290 nM (pH 8.5), has no effect on Kir1.1 and weak activity for Kir4.1 and Kir7.1.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    Kir2.1
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    1222781-70-5
  • Formula Weight
    313.82
  • Molecular Formula
    C19H19NO·HCl
  • Purity
    98%
  • Solubility
    DMSO : ≥ 125 mg/mL; 398.32 mM
  • SMILES
    Cl.COC1=CC=C(CNCC2=CC=CC3=C2C=CC=C3)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wang HR, et al. ACS Chem Biol, 2011, 6(8), 845-856.
molnova catalog
related products
  • ML365

    ML365 is a novel selective small molecule inhibitor of TASK1(KCNK3).

  • iCDK9

    iCDK9 (i-CDK9) is a potent, highly selective CDK9 inhibitor (IC50<0.4 nM, CDK9-CycT1 kinase), exhibits >600-fold selectivity toward CDK1-CycB, CDK2-CycA, CDK4-CycD1, CDK7-CycH-MAT1 and CDK8-CycC.

  • NU-6102

    A potent CDK1 and CDK2 inhibitor with IC50 of 9.5 nM and 5.4 nM against CDK1/cyclinB and CDK2/cyclinA3 respectively.